17864 Investors following Glenmark. Share this News with them.
0
Like this story, share it with millions of investors on M3
Glenmark Pharma Q4 cons PAT Rs 219 cr
Glenmark Pharma has announce its fourth quarter results. The company's Q4 consolidated PAT Rs 219 crore versus Rs 63 crore.
Glenmark Pharma has announce its fourth quarter results. The company's Q4 consolidated PAT Rs 219 crore versus Rs 63 crore.
Its consolidated revenues were up at Rs 582 crore versus Rs 339.1 crore.
Its Generic Arm net sales were at Rs 260 crore versus Rs 120 crore.
| Particulars |
Mar-08 |
Dec-07 |
Sep-07 |
Jun-07 |
| Net Sales / Interest Earned / Operating Income |
396.898 |
433.579 |
279.267 |
262.947 |
| Other Income |
15.008 |
2.26 |
1.694 |
1.084 |
| Total Income |
411.905 |
435.839 |
280.961 |
264.031 |
| Expenditure |
-281.439 |
-238.634 |
-182.47 |
-188.434 |
| Operating Profit |
130.466 |
197.205 |
98.491 |
75.598 |
| Interest |
-9.144 |
-11.764 |
-10.871 |
-9.352 |
| Profit Before Depreciation and Tax |
121.322 |
185.441 |
87.62 |
66.246 |
| Depreciation |
-8.17 |
-7.776 |
-7.506 |
-5.991 |
| Profit before Tax |
113.153 |
177.665 |
80.115 |
60.255 |
| Tax |
16.988 |
-31.238 |
-16.251 |
-11.663 |
| Net Profit |
130.141 |
146.427 |
63.864 |
48.592 |
| Equity Capital |
24.873 |
24.686 |
24.394 |
24.212 |
